| Alert |
Issuing Entity
|
Issue date | About |
|
Medical Product Alert N°2/2021 |
WHO | 26/03/2021 | Regarding the presence of a falsified product of the COVID-19 Vaccine “BNT162b2” that was discovered in Mexico in February 2021 and was recently confirmed as falsified by the World Health Organization. |
| WHO | 13/08/2021 | Regarding the presence of two falsified batches of the product remdesivir 100 mg/20 mL (5 mg/mL) identified in the WHO Region of the Americas and reported to the World Health Organization in July 2021. These products claim to be manufactured by GILEAD. However, GILEAD has confirmed that the remdesivir products listed in this alert are falsified and were not manufactured by them. | |
| WHO | 31/08/2021 | Regarding the presence of falsified COVISHIELD (ChAdOx1 nCoV-19 Corona Virus) Vaccines (Recombinant) in the WHO African Region and the WHO South-East Asia Region. The falsified products were reported to the World Health Organization in July and August 2021. The original manufacturer of COVISHIELD (Serum Institute of India Pvt. Ltd.) confirmed that the products listed in this alert are falsified. These falsified products were reported at the patient level in Uganda, India, and Myanmar. | |
|
Medical Product Alert N°6/2022 |
WHO | 5/10/2022 |
Regarding the need for caution with the following product packages: PROMETHAZINE ORAL SOLUTION BP KOFEXMALIN BABY COUGH SYRUP MAKOFF BABY COUGH SYRUP MAGRIP N COLD SYRUP due to the detection of diethylene glycol and ethylene glycol impurities in several batches of the aforementioned products. It is important to note that none of the products mentioned in the organization's letter have been imported or detected in circulation within the Arab Republic of Egypt. |
| Medical Product Alert N°7/2022 Substandard (contaminated) pediatric liquid dosage medicines |
WHO | 2/11/2022 |
Regarding the need for caution with the following product packages: TERMOREX FLURIN DMP UNIBEBI COUGH SYRUP UNIBEBI DEMAM PARACETAMOL DROPS due to the detection of diethylene glycol and ethylene glycol impurities in several batches of the aforementioned products. It is important to note that none of the products mentioned in the organization's letter have been imported or detected in circulation within the Arab Republic of Egypt |
| Medical Product Alert N°8/2022 Substandard (contaminated) METHOTREX 50mg | WHO | 27/12/2022 | Regarding the presence of substandard (contaminated) METHOTREX 50mg (Methotrexate) circulating in two countries in the WHO Eastern Mediterranean Region (Yemen and Lebanon). |
| Medical Product Alert N°1/2023 Substandard (contaminated) liquid dosage medicines identified in WHO European Region |
WHO | 11/1/2023 |
Regarding the need for caution with the following product packages: AMBRONOL SYRUP DOK - 1 MAX SYRUP due to the detection of diethylene glycol and ethylene glycol impurities in several batches of the aforementioned products listed in the alert. It is important to note that none of the products mentioned in the organization's letter have been imported or detected in circulation within the Arab Republic of Egypt. |
|
Medical Product Alert N°2/2023 TETRACYCLINE HYDROCHLORIDE OPHTHALMIC OINTMENT USP 1%
|
WHO | 22/2/2023 |
Regarding the report of a substandard product to the World Health Organization in February 2023, which was distributed to at least 55 countries. The substandard product is TETRACYCLINE HYDROCHLORIDE OPHTHALMIC OINTMENT USP 1%, manufactured by Galentic Pharma (India) Pvt. Ltd. According to the General Administration for Market Surveillance, the product mentioned in the WHO letter is not registered with the Egyptian Drug Authority and is not authorized for circulation in Egyptian markets. |
|
Medical Product Alert N°3/2023 Falsified DEFITELIO (defibrotide sodium)
|
WHO | 11/4/2023 | Regarding the product Defitelio 80 mg/mL, cases of commercial falsification were detected in the United Arab Emirates and Kyrgyzstan from the batch specified in the alert. The Central Operations Administration stated that it has not been circulated in the markets of the Arab Republic of Egypt and has not been detected. |
| WHO | 25/4/2023 | Regarding the product Defitelio 80 mg/mL, cases of commercial falsification were detected in the United Arab Emirates and Kyrgyzstan from the batch specified in the alert. The Central Operations Administration confirmed that it has not been circulated in the markets of the Arab Republic of Egypt and has not been detected. | |
| Medical Product Alert No. 5/2023 Substandard (contaminated) syrup medicines identified in WHO Region of Africa |
WHO | 19/7/2023 |
Regarding the substandard product NATURCOLD Syrup, its circulation was detected in Cameroon due to containing unacceptable levels of diethylene glycol. |
| WHO | 7/8/2023 | Regarding the product COLD OUT syrup, its circulation was detected in Iraq, and analysis revealed that the sample contained unacceptable levels of the contaminants diethylene glycol and ethylene glycol, exceeding the safe permissible limits for both substances. | |
| Medical Product Alert No. 7/2023 Falsified DEFITELIO (defibrotide) identified in the WHO Regions of Europe and South-East Asia |
WHO | 4/9/2023 | Warning regarding falsified packages of the product DEFITELIO (defibrotide) in the WHO Regions of Europe and South-East Asia. |
| Medical Product Alert No. 8/2023 Substandard (contaminated) syrup and suspension medicines | WHO | 7/12/2023 |
Regarding the detection of circulation of substandard (contaminated) syrups and oral suspensions in the WHO Regions of the Americas, Eastern Mediterranean, South-East Asia, and Western Pacific. |
|
Medical Product Alert N°1/2024: Falsified (contaminated) USP/EP PROPYLENE GLYCOL
|
WHO | 15/04/2024 |
Regarding the detection in the WHO Eastern Mediterranean Region of the circulation of falsified (contaminated) products of propylene glycol listed in the European Pharmacopoeia and the United States Pharmacopoeia.
|
|
Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide)
|
WHO | 19/06/2024 | Regarding the detection of falsified Ozempic (semaglutide) in the WHO Regions of the Americas and Europe. |
Sorry, this website does not support this browser